{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-162609","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.828534+00:00","generated_at":"2026-06-14T06:00:00.069346+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tango Therapeutics stockholders elect two Class II directors and ratify PwC as auditor","bullets":["Malte Peters, M.D. elected with 75,943,817 votes for, 3,532,483 withheld (5,145,731 broker non-votes).","Mace Rothenberg, M.D. elected with 76,746,614 votes for, 2,729,682 withheld (5,145,731 broker non-votes).","Ratification of PricewaterhouseCoopers as auditor: 84,619,141 for, 2,888 against, 2 abstain.","Quorum of 95.93% (84,622,031 of 88,209,964 shares) present at virtual annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-162609","json":"https://secwatch.observer/filing/0001193125-23-162609.json","markdown":"https://secwatch.observer/filing/0001193125-23-162609.md","text":"https://secwatch.observer/filing/0001193125-23-162609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523162609/0001193125-23-162609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523162609/d512389d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:00:00.069346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"929fa477027f36dd0fcea0a200b04d0af768fe3f","claim":"Tango Therapeutics, Inc. shareholders approved Election of two Class II director nominees to the Board of Directors at the 2023-06-06 meeting.","evidence_excerpt":"The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Malte Peters, M.D. 75,943,817 3,532,483 5,145,731 Mace Rothenberg, M.D. 76,746,614 2,729,682 5,145,731","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523162609/0001193125-23-162609-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"e63ec681e8548b4b8b6304519d0a65b0255cf91f","claim":"Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.","evidence_excerpt":"The results of the ratification were as follows: FOR AGAINST ABSTAIN 84,619,141 2,888 2","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523162609/0001193125-23-162609-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}